Partial salary support is requested for the Senior Leadership of the University of Virginia Cancer Center, consisting of the Director, Michael J. Weber, Ph.D., 50% salary;Geoffrey R. Weiss, M.D., Deputy Director for Clinical Research and Clinical Affairs, 30% salary;Sarah J. Parsons, Ph.D., Associate Director for Basic Research, 20% salary;Jay W. Fox, Ph.D., Associate Director for Shared Resources, 15% salary;and Peyton T. Taylor, M.D., Medical Director, 10% salary. In each case, the requested salary is less than the percent effort dedicated to the Cancer Center. Dr. Weber plays a leadership and oversight role in all aspects of the Cancer Center, chairing both the CCSG Executive Committee, which is the major organizational tool for fostering basic, translational, and clinical cancer research, and the Cancer Center Management Group, which integrates research and care. Dr. Weiss's role is to provide oversight of and leadership for all the clinical operations of the Cancer Center, including clinical research and care. Dr. Parsons serves as the primary liaison between the laboratory based research of the Cancer Center (Programs 1-6) and the clinical research centered in Program 7- Developmental Therapeutics. Dr. Fox offers leadership and guidance to the Shared Resource Directors and Faculty Directors for scientifically sophisticated and fiscally effective operation of the Cores for the expressed benefit of Cancer Center members. Dr. Taylor's role in the CCSG as Medical Director is to ensure that the oncology clinical enterprise functions to support clinical and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-20
Application #
8104136
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-02-01
Budget End
2011-01-31
Support Year
20
Fiscal Year
2010
Total Cost
$271,779
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications